News Chugai buys 'Asia lag' firm Renalys for $98m upfront Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.
News Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
